• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NeuroMetrix wins Chinese regulatory win for DPNcheck

NeuroMetrix wins Chinese regulatory win for DPNcheck

January 21, 2016 By Fink Densford

NeuroMetrixNeuroMetrix (NSDQ:NURO) said today it won regulatory approval in China for its DPNCheck diagnostic test for peripheral neuropathy.

DPNCheck is a point-of-care-test designed to detect diabetic peripheral neuropathy at an early stage to allow for appropriate treatment. NeuroMetrix said that DPN is the most common complication of diabetes, and affects more than 50% of people with diabetes.

“Omron skillfully guided DPNCheck through an extended regulatory process. We are now collaborating on marketing plans leading to commercial launch. We believe that DPNCheck addresses an important void in the care of persons with diabetes in China, and have discussed this topic with leading Chinese physicians over the past several years. Working closely with Omron, we believe we can develop a significant market opportunity in China,” CEO Dr. Shai Gozani said in a press release.

NeuroMetrix worked with its exclusive Chinese distributor Omron Healthcare to win the regulatory nod, and said the device is now registered as a Class II medical device.

Waltham, Mass.-based NeuroMetrix said a study published in JAMA indicated that the prevalence of Diabetes has risen to 11.6% today, and the International Diabetes Federation estimated over 96 million people in the country had diabetes in 2014.

The Chinese approval has lifted NeuroMetrix in trading today, up 4.2% to trade at $1.74 as of 12:53 p.m. EST.

Earlier this month, NeuroMetrix saw shares jump as high as 37% after announcing it won FDA 510(k) clearance for an upgraded version of its Quell wearable over-the-counter chronic pain relief device, though stocks didn’t hold onto the inertia.

The new model is designed to be controlled through a company-developed smartphone app, and has an extended battery life and advanced sleep tracking, according to the company.

Filed Under: Diabetes, Diagnostics, Regulatory/Compliance Tagged With: Neurometrix

More recent news

  • FDA adds Gradient denervation tech to advisory program
  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy